You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201921 - 201930 of 207699 results
  1. Novel and Selective AMPK Activator for the Treatment of Hepatocellular Carcinoma

    SBC: NOVATARG, INC.            Topic: NCI

    Project Summary/Abstract Liver cancer, primarily hepatocellular carcinoma (HCC), accounts for ~662,000 deaths each year and is the third leading cause of death from cancer worldwide. The age-adjusted incidence of HCC tripled between 1975 and 2005 in the US, and primary liver cancer mortality rates have increased faster than mortality for any other tumor type. One- and 3-year survival rates were 36 ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Methods for improving the properties of antibody-drug conjugates

    SBC: IGENICA, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Antibody drug conjugates (ADCs), a rapidly growing class of targeted therapeutics, represent a promising new approach toward improving both the selectivity and the cytotoxic activity of cancer drugs. Although several ADCs have demonstrated recent clinical success, the utility of most ADCs currently in development is limited by cumbersome synthetic processes, in ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Biomarker Breast Pap Test

    SBC: SILBIOTECH, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): This Phase I research proposal is to investigate the feasibility of developing a novel Biomarker Breast PapTest for screening Nipple Aspirate Fluid (NAF) and detecting breast cancers at the tumor-in-formation stage before mammographically detectable tumors are developed. Although there is a slight decline in deaths from breast cancer in recent years, it conti ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Real-time assessment of surgical margins with enhanced contract optical imaging

    SBC: PHYSICAL SCIENCES INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Physical Sciences, Inc. (PSI), in collaboration with Massachusetts General Hospital proposes to investigate the use of a high sensitivity/specificity cancer targeting agent and of a novel fluorescence-guided microscopy(FGM) scheme for intraoperative assessment of surgical margins in breast cancer patients. The contrast agent will be used to label cancer cells a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Discovery of inhibitors of the metabolic oncogene 3-phosphoglycerate dehydrogenas

    SBC: Kadmon Corporation, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Many profound metabolic alterations have been described in solid tumors which present attractive therapeutic targets. One recently described metabolic oncogene is 3- phosphoglycerate dehydrogenase (PHGDH), the rate-limiting step in the pathway synthesizing serine and glycine for proteins, lipids, folate and nucleotide metabolism. The PHGDH gene is amplified a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Targeting the Core Binding Factor tumor suppressor in MLL-fusion AML

    SBC: P2D, INC            Topic: NCI

    DESCRIPTION (provided by applicant): RUNX1 is considered a beneficial tumor suppressor in myeloid neoplasms. Inhibition of RUNX1 function has been implicated as an important mechanistic event in the development of core-binding factor-(CBF)-leukemia and MLL-fusion leukemia. Inactivating RUNX1 mutations are frequently found in patients with acute myeloid leukemia (AML). However, RUNX1 mutation is us ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Deimmunized TLR5 Agonist for Anticancer Therapy

    SBC: BUFFALO BIOLABS, LLC            Topic: NCI

    ABSTRACT: Radiotherapy is widely used to treat various types of cancer; however, its effectiveness is frequently limited by severe adverse effects resulting from radiation-induced damage to normal tissues in the tumor environment. Due to the scale of thisproblem and the current lack of safe and effective countermeasures against radiation toxicity, development of such agents is of broad significanc ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. TRAIL Upregulation by TIC10 Analogs

    SBC: PROVID PHARMACEUTICALS INC.            Topic: NCI

    Project Summary/Abstract TIC10 (ONC201) is a first-in-class antitumor agent and small molecule inducer of the TRAIL gene which was identified in a high-throughput small molecule library screen in the lab of our collaborator, Dr. Wafik El-Deiry at Penn State University and has been shown to have preclinical efficacy in several difficult-to-treat disease settings that include unmet clinical needs su ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Synergy between MAG-1 and Cyclophosphamide for Treatment of Recurrent SCLC

    SBC: Woomera Therapeutics, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): There is currently no effective treatment for recurrent small-cell lung cancer (rSCLC). The objective of this project is to utilize a monoclonal antibody, MAG-1, to develop new, rational, and successful treatment of rSCLC. The hypothesis being tested is that a cancer -specific provasopressin antigen, called GRSA, present at the surface of these tumors will prov ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Correcting Aberrant Splicing of the Human CD22 Gene

    SBC: RETROTHERAPY, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): B-precursor acute lymphoblastic leukemia (BPL) is the most common form of cancer in children and adolescents. This project addresses an urgent and unmet need for the treatment of aggressive, treatment refractory BPL. Two recent studies have found a deletion of CD22 exon 12 (CD22?E12) in primary leukemic cells in the vast majority of pediatric patients with poor ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government